Skip to content
Screener

Stryker SYK MedSurg and Neurotechnology: — D&A

Other segment segments

Orthopaedics
$107M—

Similar metrics at other companies

Haemonetics logo
HAEMedSurg — D&A
$13.48M-9.2%
Primoris Services logo
PRIMU And D — D&A
$14.2M-2.7%
World Kinect logo
WKCLand — D&A
$8.9M-36.4%
MYR Group logo
MYRGT&D — D&A
$15.92M+11.7%
Taboola.com Ltd. logo
TBLAD&A
$7.31M-21.7%
Brink's, Inc. logo
BCOD&A
$79.1M+32.3%

Other financials

Income statement

See full
Revenue$6.6B+9.4%
Gross profit$4.5B+17.1%
Operating income$1.7B+49.1%
Net income$1.3B+44.3%
EPS (diluted)$3.30+44.1%

Balance sheet

See full
Cash & equivalents$3.4B+42.8%
Total debt$14.2B-15.2%
Total assets$47.9B+3.5%

Cash flow

See full
Operating cash flow$1.3B+13.5%
CapEx$202.0M+10.4%
Free cash flow$1.1B+14.1%

Valuation

See full
Market cap$129.28B-9.8%
Enterprise value$140.08B-11.2%
P/E34.7×-14.5×
P/S5×-1.0×

Profitability

See full
Gross margin65%+0.8pp
Operating margin21.4%+6.2pp
Net margin14.4%+2.2pp
FCF margin18.2%+1.3pp

Returns & leverage

See full
Return on equity32.8%—
Debt / equity0.8×—
Current ratio2.2×+0.4×

Where this comes from

Reported directly by Stryker in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Stryker’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 11:10 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000310764-26-000031
Segment ResultsThree Months / 2026Three Months / 2025
MedSurg and Neurotechnology$930$859
Orthopaedics880925
Segment selling, general and administrative expenses$1,810$1,784
MedSurg and Neurotechnology$55$48
Orthopaedics119107
Segment depreciation and amortization$174$155
Corporate and Other$43$39
Amortization of intangible assets180167

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Stryker's medsurg and neurotechnology: — D&A?
Stryker (SYK) reported medsurg and neurotechnology: — D&A of $55M in Q1 2026.
How has Stryker's medsurg and neurotechnology: — D&A changed year-over-year?
Stryker's medsurg and neurotechnology: — D&A increased by 14.6% year-over-year, from $48M to $55M.
What is the long-term trend for Stryker's medsurg and neurotechnology: — D&A?
Over 4 years (2021 to 2025), Stryker's medsurg and neurotechnology: — D&A has grown at a -18.5% compound annual growth rate (CAGR), from $518M to $228M.
What does medsurg and neurotechnology: — D&A mean?
Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the MedSurg and Neurotechnology segment. This non-cash expense reflects the wear and tear of manufacturing equipment and the expiration of acquired intellectual property. It is essential for understanding the segment's true cash-generating capability.

Ask your AI about Stryker's medsurg and neurotechnology: — d&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude